Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors

被引:11
|
作者
Ribone, Sergio R. [1 ]
Quevedo, Mario A. [1 ]
Madrid, Marcela [1 ]
Brinon, Margarita C. [2 ]
机构
[1] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farm, RA-5000 Cordoba, Argentina
[2] Pittsburgh Supercomp Ctr, Pittsburgh, PA 15213 USA
基金
美国国家科学基金会;
关键词
DRUG-RESISTANCE; POSITIONAL ADAPTABILITY; HIGHLY POTENT; HIV-1; RT; RILPIVIRINE; MECHANISMS; ETRAVIRINE; DISCOVERY; DOCKING; BINDING;
D O I
10.1021/ci1001636
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The binding of several classes of nonnucleoside reverse transcriptase inhibitors (NNRTIs) to wild-type (wtRT) and K103N mutant (mRT) human immunodeficiency virus type 1 (HIV-1) reverse transcriptase is studied by molecular dynamics and energy decomposition techniques. The imidoylthiourea (ITU), diaryltriazine (DATA), and diarylpyrimidine (DAPY) NNRTIs studied maintain the hydrogen bond with Lys101 during the 3 ns molecular dynamics trajectories. When bound to mRT, all the DAPYs studied establish hydrogen bonds with Glu138; among these, those of the potent inhibitors TMC120 and TMC125 are water-mediated. The molecular interactions of the NNRTIs in the binding pocket are correlated to the drugs' potency. Quantitative free energy analyses show a linear relationship between the van der Waals energetic component and the potency against wtRT. The molecular basis of the interaction between NNRTIs and RT presented here provide quantitative approaches for the design of novel effective anti-HIV drugs.
引用
收藏
页码:130 / 138
页数:9
相关论文
共 50 条
  • [1] Etravirine and Rilpivirine: Nonnucleoside Reverse Transcriptase Inhibitors with Activity Against Human Immunodeficiency Virus Type 1 Strains Resistant to Previous Nonnucleoside Agents
    Fulco, Patricia Pecora
    McNicholl, Ian R.
    PHARMACOTHERAPY, 2009, 29 (03): : 281 - 294
  • [2] STRUCTURE OF THE BINDING-SITE FOR NONNUCLEOSIDE INHIBITORS OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SMERDON, SJ
    JAGER, J
    WANG, J
    KOHLSTAEDT, LA
    CHIRINO, AJ
    FRIEDMAN, JM
    RICE, PA
    STEITZ, TA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 3911 - 3915
  • [3] Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance
    Gupta, Soumi
    Fransen, Signe
    Paxinos, Ellen E.
    Stawiski, Eric
    Huang, Wei
    Petropoulos, Christos J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 1973 - 1980
  • [4] Human immunodeficiency virus type 1 reverse transcriptase
    Hottiger, M
    Hubscher, U
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1996, 377 (02): : 97 - 120
  • [5] Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
    Selhorst, Philippe
    Vazquez, Ana C.
    Terrazas-Aranda, Katty
    Michiels, Johan
    Vereecken, Katleen
    Heyndrickx, Leo
    Weber, Jan
    Quinones-Mateu, Miguel E.
    Arien, Kevin K.
    Vanham, Guido
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) : 1403 - 1413
  • [6] Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection
    Elsayed, Raghda K.
    Caldwell, David J.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (03) : 193 - 205
  • [7] Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor
    Fletcher, P.
    Harman, S.
    Azijn, H.
    Armanasco, N.
    Manlow, P.
    Perumal, D.
    de Bethune, M.-P.
    Nuttall, J.
    Romano, J.
    Shattock, R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) : 487 - 495
  • [8] Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1
    Corbau, Romuald
    Mori, Julie
    Phillips, Chris
    Fishburn, Lesley
    Martin, Alex
    Mowbray, Charles
    Panton, Wendy
    Smith-Burchnell, Caroline
    Thornberry, Adele
    Ringrose, Heather
    Knoechel, Thorsten
    Irving, Steve
    Westby, Mike
    Wood, Anthony
    Perros, Manos
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4451 - 4463
  • [9] INHIBITION OF REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND CHIMERIC ENZYMES OF HUMAN IMMUNODEFICIENCY VIRUSES TYPE-1 AND TYPE-2 BY 2 NOVEL NONNUCLEOSIDE INHIBITORS
    RUBINEK, T
    MCMAHON, JB
    HIZI, A
    FEBS LETTERS, 1994, 350 (2-3) : 299 - 303
  • [10] Properties of human immunodeficiency virus type 1 reverse transcriptase recombination upon infection
    Sakuragi, Sayuri
    Shioda, Tatsuo
    Sakuragi, Jun-ichi
    JOURNAL OF GENERAL VIROLOGY, 2015, 96 : 3382 - 3388